FEED ENvue Medical, Inc.
Listings ·
Each 12 shares will combine into one, which would reduce the 11,084,616 common shares outstanding to about 923,718. The release says trading begins on the Nasdaq Capital Market on September 1, 2026, under the FEED symbol.
The company can sell up to $50.0 million of common stock to one institutional investor, and the same day it amended a Series H preferred stock agreement with that investor.
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $1.8 million | $909,000 |
| Net income (loss) | -$18.2 million | -$3.7 million |
| Cash from operations | -$9.4 million | -$2.5 million |
| Cash and equivalents | $4.2 million | $752,000 |
Our latest story on this, dated Aug 28, 2026: "ENvue Medical announces 1-for-12 reverse stock split effective September 1". The story links the filing or release it is based on. Read the story.
ENvue Medical, Inc. trades under the ticker FEED on OTC.
ENvue Medical, Inc. is listed on OTC.
Our directory records ENvue Medical, Inc. under United States.
aibio.space lists ENvue Medical, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
ENvue Medical, Inc. reported a net loss of $18.2 million for the fiscal year ended Dec 31, 2025, and used $9.4 million of cash in operations, per its annual report to the SEC.
$1.8 million in the fiscal year ended Dec 31, 2025, per its annual report.
$1.1 million in cash at Jun 30, 2026, per its 10-Q.
Our latest story on ENvue Medical, dated Aug 28, 2026: "ENvue Medical announces 1-for-12 reverse stock split effective September 1". Each 12 shares will combine into one, which would reduce the 11,084,616 common shares outstanding to about 923,718. The release says trading begins on the Nasdaq Capital Market on September 1, 2026, under the FEED symbol. Source.
Our latest financing story, dated Aug 12, 2026: "ENvue Medical agrees to a $50 million committed equity facility". The company can sell up to $50.0 million of common stock to one institutional investor, and the same day it amended a Series H preferred stock agreement with that investor. Source.
Press Follow on this page to add ENvue Medical to your Following list, or subscribe to the aibio.space newsletter. We have published 2 stories naming ENvue Medical so far, in Financings, Listings.
Reported a reverse stock split. SEC Form 8-K (Items 5.03,8.01,9.01). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,9.01). Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio